In a diabetes-specific population (TRANSCEND-T2D-1, 40 weeks), weight loss was 16.8% substantially lower, consistent with GLP-1 class patterns
Its use as a weight loss aid is off-label, meaning weight loss is a side effect of the medication that healthcare providers may use to the patients benefit
A decade of progress in type 2 diabetes and cardiovascular disease: Advances in SGLT2 inhibitors and GLP-1 receptor agonistsa comprehensive review
Fras JP, Dahl D, Bhatt DL, et al
The serendipitous discovery of exendin-4 led to the development of exenatide immediate-release (exenatide IR, Byetta), a synthetic version of exendin-4 with C-terminal amidation to enhance its stability [ Figure 2 , Table 1 ], which became the first FDA-approved GLP-1RA in 2005 for the treatment of T2DM in adults [ Table 2 ]
An ultrasensitive biosensor for high-resolution kinase activity imaging in awake mice